BioOutsource to Host Webinar on Biosimilar Comparability on Thursday, 12 February
Free Webinar to Explore Comparability Challenges Faced by Developers of Biosimilars
GLASGOW, Scotland and CAMBRIDGE, Mass. – 9 February 2015 – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterization for the biopharmaceutical industry, today announced that it will be hosting a free webinar on Thursday, 12 February, at 3:00 p.m. GMT / 10:00 a.m. EST.
“With Pfizer having just announced a $17 Billion acquisition of Hospira, largely to boost its biosimilars pipeline, it is clear that the biosimilars market is booming, and estimated by Pfizer to ramp up to $20 Billion by 2020,” commented BioOutsource CEO, Gerry MacKay. “Moreover, with the FDA having recently issued draft guidelines that describe a requirement for ‘fingerprint-like similarity,’ the biosimilars field presents both enormous opportunity and complex challenges. It is essential, then, for developers to stay abreast of the latest developments that directly affect their bottom line. In that case we have developed this free webinar which will explore in detail the comparability challenges facing developers and manufacturers of biosimilars.”
With a specific emphasis on the critical importance of going through a comprehensive and orthogonal characterization process using assays capable of detecting subtle differences between molecules, the webinar will be hosted by BioOutsource scientists Sarah Stone, PhD, and Andrew Baron, PhD. Dr. Stone is an expert in the characterization of biosimilar monoclonal antibody-based therapies for some of the most well-known molecules such as Rituximab and Etanercept. With a PhD in neuroscience, Dr. Baron developed some of BioOutsource’s most popular off-the-shelf assay packages to support biosimilar development, and leads a dedicated team performing bioassays and and binding assays in BioOutsource’s Biosimilar Centre of Excellence.
Mr. MacKay added, “We invite anyone involved in biosimilar development, from chief executives to chief scientific officers to heads of regulatory affairs, to join us for this unique learning event.”
More information and complimentary registration is available at the following link: http://ow.ly/Il1lp.